Company news

Precision BioSciences, Inc. news in 2020

Precision BioSciences, Inc.'s news releases, calls and decks from 2020, newest first.

View company

Precision BioSciences Announces Executive Leadership Change

December 13, 2020

Precision BioSciences Reports Positive Interim Results from PBCAR0191 Phase 1/2a Trial in Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL) and R/R B-cell Acute Lymphoblastic Leukemia (B-ALL)

December 3, 2020

Lilly and Precision BioSciences Announce Genome Editing Research Collaboration and License Agreement

November 19, 2020

Precision BioSciences Reports Third Quarter 2020 Financial Results and Provides Business Update

November 9, 2020

Precision BioSciences to Report Third Quarter 2020 Financial Results on November 10, 2020

November 2, 2020

Precision BioSciences Announces U.S. Patent Trial and Appeal Board Upholds Allogeneic CAR T Patents

October 14, 2020

Precision BioSciences Appoints Alex Kelly as Chief Corporate Affairs Officer

October 13, 2020

Precision BioSciences and SpringWorks Therapeutics Announce Clinical Collaboration to Evaluate PBCAR269A in Combination with Nirogacestat in Patients with Relapsed or Refractory Multiple Myeloma

September 20, 2020

Precision BioSciences and Servier Expand CAR T Oncology Development Collaboration with Four New Programs Targeting Hematological and Solid Tumors

September 16, 2020

Precision BioSciences Receives Fast Track Designation from U.S. Food and Drug Administration for PBCAR269A, an Investigational Allogeneic CAR T Therapy for Relapsed/Refractory Multiple Myeloma

September 8, 2020

Precision BioSciences Receives Fast Track Disease Designation from U.S. Food and Drug Administration for PBCAR0191 Investigational Allogeneic CAR T Cell Therapy

August 18, 2020

Precision BioSciences Reports Second Quarter 2020 Financial Results and Provides Business Update

August 12, 2020

Precision BioSciences Regains Rights to In Vivo Hepatitis B Virus Program

July 5, 2020

Precision BioSciences Announces Dosing of First Patient in Phase 1/2a Clinical Trial of PBCAR269A for Multiple Myeloma

June 7, 2020

Precision BioSciences Reports First Quarter 2020 Financial Results and Provides Business Update

May 14, 2020

Precision BioSciences Announces Presentations at the American Society of Gene & Cell Therapy 23rd Annual Meeting

April 27, 2020

Precision Biosciences Appoints Dora Alvarado as Senior Vice President of Human Resources

April 14, 2020

Precision BioSciences Announces Dosing of First Patient in Phase 1/2a Clinical Trial of PBCAR20A for Relapsed/Refractory NHL, CLL, and SLL

April 6, 2020

Precision BioSciences Strengthens Board of Directors with Appointment of Geno Germano

March 10, 2020

Precision BioSciences Reports Fourth Quarter and Fiscal Year 2019 Financial Results and Provides Business Update

March 9, 2020

Precision BioSciences to Report Fiscal Year and Fourth Quarter 2019 Financial Results and Present at Upcoming Investor Conferences

February 20, 2020

Precision BioSciences Announces FDA Acceptance of IND for PBCAR269A, a BCMA Targeted Genome Edited Allogeneic CAR T Therapy Candidate for Multiple Myeloma

January 12, 2020

Decks in 2020